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Complement receptor 3 (CR3) is expressed abundantly on natural killer (NK) cells; how-
ever, whether it plays roles in NK cell-dependent tumor surveillance is largely unknown. 
Here, we show that CR3 is an important negative regulator of NK cell function, which 
has negative impact on tumor surveillance. Mice deficient in CR3 (CD11b−/− mice) 
exhibited a more activated NK phenotype and had enhanced NK-dependent tumor 
killing. In a B16-luc melanoma-induced lung tumor growth and metastasis model, mice 
deficient in CR3 had reduced tumor growth and metastases, compared with WT mice. 
In addition, adaptive transfer of NK cells lacking CR3 (into NK-deficient mice) medi-
ated more efficient suppression of tumor growth and metastases, compared with the 
transfer of CR3 sufficient NK cells, suggesting that CR3 can impair tumor surveillance 
through suppression of NK cell function. In vitro analyses showed that engagement of 
CR3 with iC3b (classical CR3 ligand) on NK cells negatively regulated NK cell activity 
and effector functions (i.e. direct tumor cell killing, antibody-dependent NK-mediated 
tumor killing). Cell signaling analyses showed that iC3b stimulation caused activation 
of Src homology 2 domain-containing inositol-5-phosphatase-1 (SHIP-1) and JNK, 
and suppression of ERK in NK cells, supporting that iC3b mediates negative regulation 
of NK cell function through its effects on SHIP-1, JNK, and ERK signal transduction 
pathways. Thus, our findings demonstrate a previously unknown role for CR3 in 
dysregulation of NK-dependent tumor surveillance and suggest that the iC3b/CR3 
signaling is a critical negative regulator of NK cell function and may represent a new 
target for preserving NK cell function in cancer patients and improving NK cell-based 
therapy.
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inTrODUcTiOn
Natural killer (NK) cells comprise 2–13% of all circulating lymphocytes and mediate spontaneous 
killing of tumor, foreign cells, and aberrant host cells by exocytosis of granzyme- and perforin-
containing cytoplasmic granules. They also produce cytokines (e.g., IFN-γ) to regulate other 
immune cell functions (1, 2). NK cells express an array of receptors including the activating receptors 
2Liu et al. CR3 Suppresses NK Tumor Surveillance
Frontiers in Immunology | www.frontiersin.org November 2017 | Volume 8 | Article 1602
(e.g., NKp46) and inhibitory receptors [e.g., CD158b (in man), 
ly49I/C (in mice)] and cytokine/chemokine receptors (3). 
Through these receptors, NK cells can sense and respond to many 
distinct stimuli and undergo functional modulation participating 
in immune responses under both physiological and pathological 
conditions (4, 5).
In the context of malignancy, both clinical and experimental 
studies have provided substantial evidence suggesting that 
NK cells are fundamental to elimination of tumor cells and the 
control of tumor metastasis (6, 7). It has been shown that NK cells 
can eliminate tumor cells from the circulation, prevent the dis-
semination of metastatic tumors, and suppress tumor outgrowth 
in experimental models (8–10). In the clinic, tumor infiltration by 
NK cells is associated with a better prognosis in several types of 
carcinomas (11–14). In hematopoietic stem-cell transplantation 
(HSCT) and adoptive NK cell immunotherapy, NK cells are criti-
cal for controlling and/or eradicating high-risk leukemia (15–17). 
In anti-tumor antibody therapy, NK-mediated killing is required 
for curative efficacy of antibody. Together, these observations 
provide compelling evidence that NK cells play a significant role 
in tumor surveillance and can be used in therapeutic settings 
against cancer. However, tumor cell-induced excessive inflam-
matory responses can promote the development of immunosup-
pressive microenvironment leading to compromised NK  cell 
function which enhances tumor growth and metastasis (18–20); 
current NK cell-based therapy also faces a lot of challenges, e.g., 
functional decline of the reconstituted NK cells in acute myeloid 
leukemia patients following HSCT and rapid loss of cytotoxic 
activity of infused NK  cells that have been expanded ex vivo 
(21, 22). The factors that could dysregulate NK cell function in 
both situations are not clear. More thorough understanding of 
mechanisms that regulate NK cell function and identifying the 
mediators that lead to NK dysfunction are required for improve-
ment of NK-based therapy.
The complement system is an integral part of innate immunity 
(23). Spontaneous and well-controlled complement activation 
occurs under physiological conditions. Increased complement 
activation takes place in response to infection and to a diverse 
set of innate molecules and signatures, particularly under 
pathological conditions. Once activated, the complement cascade 
generates a set of effector molecules, including the large fragment 
C3b and its further degraded products iC3b and C3d, the small 
fragments (C3a and C5a) and the terminal product C5b-9. Apart 
from mediating a direct killing of foreign cell/pathogens by 
C5b-9, activation of complement also plays important roles in 
immune regulation through engagement of complement recep-
tors (e.g., C3aR, C5aR, CR1, CR2, and CR3) on immune cells with 
respective complement cleavage products (e.g., C3a, C5a, C3b, 
C3d, and iC3b) (23–26).
Complement receptor 3 [also known as Mac-1, integrin α(M)β 
(2), CD11b/CD18] is heterodimeric leukocyte adhesion molecule 
and abundantly expressed by NK  cells both in man and mice. 
iC3b (inactive product of the cleavage fragment C3b) is the clas-
sic ligand for CR3, although non-complement molecules such as 
ICAM-1 and fibrinogen can also function as a ligand for CR3. 
iC3b either in fluid phase (with a relative low affinity) or bound 
to biological surfaces can express biological activities through 
interaction with CR3 (27, 28). It has been shown that iC3b-CR3 
interactions had suppressive effects on antigen-presenting cells 
and immature dendritic cells, suggesting a negative regulatory 
role of CR3 in immune cells (29, 30). In terms of tumor, it has 
been shown that increased soluble iC3b levels were associated 
with the progression of pancreatic adenocarcinoma, suggesting 
iC3b as an early biomarker and a potential risk factor for pancre-
atic carcinoma (31).
Given the abundant expression of CR3 in NK cells, negative 
regulatory roles of iC3b/CR3 axis in other immune cells and the 
association of iC3b with tumor progression, we hypothesized 
that iC3b/CR3 signaling is an important negative regulator 
of NK  cell function, which may have negative impact on 
tumor surveillance and hinder the efficiency of NK-based and 
antibody-based therapies. To test the hypothesis, we employed 
CR3 functional deficient (CD11b−/−) mice and several in  vivo 
models (i.e., an NK-dependent peritoneal tumor elimination 
model, a pulmonary B16 melanoma metastases model, and 
the metastases model combining adaptive transfer of NK cells 
in NK-deficient mice). We assessed whether CR3-deficient 
NK cells have enhanced tumor cell killing capacity and whether 
CR3 deficiency and more specifically CR3-deficient NK  cells 
protect mice from pulmonary metastatic melanoma. We also 
performed in vitro analysis to define the role of CR3 in NK cells. 
We examined the effects of iC3b-containing serum and iC3b-
apoptotic cells on NK cell activation and effector functions using 
freshly prepared human NK cells. We explored the intracellular 
signaling pathways responsible for the action of iC3b on NK cell 
functional regulation. Our results indicate that CR3 signaling 
negatively regulates NK  cell function and impairs NK  cell-
dependent tumor surveillance in mice.
MaTerials anD MeThODs
reagents
Normal human serum and C3-depleted serum were purchased 
from Sigma-Aldrich (Shanghai, China). Cell culture medium 
and supplements were purchased from Invitrogen China 
Limited (Beijing, China). Recombinant human IL-2 was pur-
chased from Peprotech China (Suzhou, China). Rituximab was 
purchased from Roche (Mannheim, Germany). The following 
fluorochrome-conjugated monoclonal antibodies were used 
for the flow cytometry detection: FITC-conjugated anti-mouse 
CD3 (145-2C11), anti-human CD3e (SP34), PE-conjugated 
anti-mouse CD69 (G235-2356), anti-human IFN-γ (4S. B3), 
-Granzyme B (GB11) were purchased from BD Biosciences 
(Oxford, UK). APC-conjugated anti-mouse NK1.1 (PK136), 
anti-human CD56 (B159), PE-conjugated anti-mouse NKp46 
(29A1.4), CD107a (1D4B), Ly49I/C (YLI-90), and anti-human 
CD54 (HA58), NKp46 (9E2), CD69 (FN50), CD158b (DX27), 
CD107a (H4A3), and perforin (dG9) were all purchased from 
BioLegend (San Diego, CA, USA). Antibody reagents used 
in signaling pathway studies [i.e., anti-phospho-Src homol-
ogy 2 domain-containing inositol-5-phosphatase-1 (SHIP1) 
(Tyr1020), -SAPK/JNK (Thr183/Tyr185), -ERK1/2 (Thr202/
Tyr204), -p38 (Thy180/Tyr182), -Akt (Ser473), and anti-SHIP1, 
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-ERK1/2, -JNK, -Akt, and -p38 antibodies] and signaling pathway 
inhibitors (i.e., ERK inhibitor U0126, JNK inhibitor SP600125) 
were purchased from Cell Signaling Technology (Danvers, MA, 
USA). SHIP1 inhibitor (3-alpha-aminocholestane, 3AC) was 
purchased from Merck (Beijing, China). Mouse monoclonal 
anti-human iC3b (neo) Ab and the MicroVue iC3b Enzyme 
Immunoassay kit was from purchased Quidel (San Diego, 
CA, USA). Rat monoclonal anti-mouse C3b/iC3b/C3c (2/11) 
was purchased from Hycult Biotech (Uden, the Netherlands). 
Cytofix/Cytoperm™ Kit with GolgiPlug™ was purchased from 
BD Biosciences. ToxiLight™ Non-destructive Cytotoxicity 
BioAssay Kit was purchased from Lonza (Rockland, ME, USA).
Mice
CD11b−/− mice (Itgamtm1Rws) were purchased from Jackson 
Laboratory (Bar Harbor, ME, USA), E4BP4−/− mice (32) were 
provided by Professor H. Brady. Both strains have been back-
crossed onto C57BL/6 strain for at least 10 generations. C57BL/6 
WT mice were purchased from Vital River Laboratories (Beijing, 
China). Male mice (6–8 weeks old) were used in all experiments; 
all mice were maintained in specific pathogen-free conditions. 
The Ethics Review Committee for Animal Experimentation 
at Xi’an Jiaotong University approved and oversaw all mouse 
experiments.
lung Metastasis Model
Mice [WT or CD11b−/− or NK  cell-deficient mice (E4bp4−/− 
mice)] were inoculated with luciferase-labeled B16 melanoma 
cells (B16-luc cells, 1 ×  106 in 100  µl PBS) by intravenous tail 
injection at day 0. At day 7 and day 14, mice were shaved, 
anesthetized, and administered with 30  µg D-luciferin (R&D 
system, Minneapolis, MN, USA) by intraperitoneal injection. 
Bioluminescence images were acquired using the IVIS Lumina 
XRMS Series III (Xenogen, San Francisco, CA, USA). All images 
were analyzed using Living Image software (Xenogen). Average 
radiance (p/s/cm2/sr) is used to determine the tumor load, which 
refers to the number of photons (p) per second that are leaving 
a square centimeter of tissue and radiating into a solid angle 
of 1  sr. At day 14, mice were sacrificed, the number of tumor 
nodules on lung surface were also enumerated manually. For 
adaptive transfer of NK cell experiment, E4bp4−/− mice received 
5 × 105 FACS-sorted NK1.1+CD3− NK cells prepared from WT or 
CD11b−/− mice by intravenous tail injection on the day of tumor 
cell inoculation. The mice received a second dose of NK cells on 
day 7 following the inoculation.
nK-Dependent Peritoneal Tumor 
elimination Model
RMA-s (NK-sensitive lymphoma cells) and RMA cells (NK 
non-sensitive lymphoma cells) were incubated with different 
concentrations of CFSE (5 and 0.5 µM, respectively) for 10 min 
at 37°C. After wash, RMA-s cells (CFSEhi) (2.5  ×  106) and 
RMA cells CFSElo (1 ×  106) were mixed and injected into the 
peritoneum of WT or CD11b−/− mice. 4 h after tumor injection, 
peritoneal lavage cells were collected and analyzed by flow cytom-
etry, and the various populations of labeled cells were detected 
by their differential CFSE fluorescence intensities. To calculate 
the remaining RMA-s cells, the following formula was used: 
remaining RMA-s cells = (ratio of recovered cells × the number 
of injected RMA cells), ratio = (percentage of RMA-s [CFSEhi]/
percentage of [CFSElo]).
Preparation of ic3b (soluble or Bound)
To generate iC3b containing serum, normal human serum and 
C3-depleted serum (the control) were treated with zymosan 
(0.5 mg/ml, Sigma) at 37°C for 40 min, centrifuged to remove 
insoluble particles. To prepare membrane-bound iC3b, Jurkat 
T cells were cultured in RPMI-1640 containing 10% FCS until 
reach plateau-phase, and further cultured in medium containing 
2% FCS at 2 × 106 cells/ml for two and half hours, to promote 
apoptosis. Apoptotic Jurkat cells were then incubated with 
RPMI-1640 containing 20% normal human serum for 1 h, and 
the deposition of iC3b on the surface of apoptotic cells was 
analyzed by flow cytometric analysis. Apoptotic cells incubated 
with C3-depleted serum having no iC3b deposition served as the 
control.
Preparation of human nK cells
Human peripheral blood samples were obtained with informed 
consent from a panel of seven healthy donors (male:female, 4:3) 
aged between 24 and 41 from the department. The study had 
been approved by the School Human Studies Ethics Committee. 
Peripheral blood mononuclear cells (PBMCs) were obtained 
by Ficoll-Hypaque gradient centrifugation (Lymphoprep, PAA 
laboratories, Pasching, Austria). Total NK  cells were isolated 
from PBMCs using NK isolation kit (Miltenyi Biotec, Bergisch 
Gladbach, Germany) according to the manufacturer’s instruc-
tions. After the isolation, the purity of the CD56+CD3− NK cell 
preparation was routinely more than 90%. Purified human 
NK  cells were cultured in completed RPMI-1640 (10% heat-
inactivated FCS, 50  µM 2-mecaptoethanol, 2  mM glutamine, 
50 U/ml penicillin and 50 μg/ml streptomycin) supplemented 
with 50 pg/ml recombinant human IL-2 at 37°C in 5% CO2. In 
some experiments, iC3b-containing serum (10%) or iC3b-bound 
apoptotic cells (at 1:1 NK-apoptotic cell ratio) were added into 
culture medium for indicated time period.
Phenotypic and Functional analyses of 
human nK cells by Flow cytometry
For NK cell activation phenotype, NK cells were stained with a 
cocktail of directly conjugated antibodies against surface mol-
ecules, including anti-CD56 (APC), -CD3e (FITC), -CD54 (PE), 
-CD69 (PE), -NKp46 (PE), and -CD158b (PE) and followed by 
flow cytometry. For NK cell function, NK cells were cocultured 
with K562 cells at 1:1 effector–target (E/T) ratio for 1  h and 
followed by intracellular staining for CD107a, granzyme B and 
perforin and followed by flow cytometry. For IFN-γ production, 
NK cells were cocultured with K562 cells for 2 h, thereafter, BD 
GolgiStop™ Protein Transport Inhibitor (contains monensin) 
was added to the coculture and incubation for another 4 h. The 
cells were then stained intracellularly with anti-IFN-γ antibody 
and followed by flow cytometry. In some experiments, NK cells 
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were pretreated with specific inhibitor of SHIP-1 (3AC) (33) 
(0.5 µM), ERK (U0126) (10 µM), and JNK (SP600125) (25 µM), 
or vehicle controls (culture medium containing 0.002% ethanol 
for 3AC, and 0.1% DMSO for both U0126 and SP600125) for 
16 h. All the experiments were performed using FACS Calibur 
(Becton Dickinson). Data were analyzed using FlowJo software 
(Tree Star, Ashland, OR, USA). Mean fluorescence intensity 
(MFI) and percentage positive cells were determined.
nK cytotoxicity assay
In vitro cytotoxicity assay was performed using the ToxiLight™ 
Non-destructive Cytotoxicity BioAssay Kit (Lonza) following 
the supplier’s instruction. Briefly, NK  cells were treated with 
bound iC3b for 24 h, and after washing, the NK cells were cocul-
tured with target cells [with NK cell/target cell (E/T) ratios from 
20:1 to 1:1] for another 4 h at 37°C. For direct tumor cell killing, 
K562 cells were used as target cells. For antibody-dependent 
cell-mediated cytotoxicity (ADCC), Raji cells were used, and 
Rituximab (5  µg/ml) was present in the coculture. At the end 
of the incubation, 100 µl of adenylate kinase detection reagent 
was added to each well, the luminous intensity was detected by 
SpectraMax® i3 (Molecular Devices, USA).
Preparation of Murine nK cells
Murine NK  cells were isolated from splenocytes by negative 
selection using the mouse NK cell isolation kit (Miltenyi Biotec) 
and further sorted by BD FACS Aria II (Becton Dickinson, San 
Jose, CA, USA) using anti-NK1.1 and -CD3 antibodies. The 
purity of sorted NK1.1+CD3− cells was consistently more than 
95%, as determined by flow cytometry.
Functional analysis of Murine nK cells by 
Flow cytometry
2 ×  105 purified murine NK  cells were cocultured with Yac-1 
tumor targets (a 2:1 E/T ratio) for 90 min. The cells were prein-
cubated with mouse anit-CD16-CD32 mAb to block Fc receptors 
and then with fluorochrome-conjugated anti-NK1.1, -CD3, and 
-CD107a antibody, followed by flow cytometry. For IFN-γ pro-
duction, NK cells were incubated with Yac-1 for 1 h, GolgiPlug 
was added to the cultures, which were incubated for another 
4 h. The cells were then stained intracellularly with anti-IFN-γ 
antibody and followed by flow cytometry.
Western Blot
Natural killer cells were incubated with bound iC3b and lysed 
at indicated times. Equal amounts of protein were subjected to 
SDS-PAGE electrophoresis, and transferred onto PVDF mem-
branes. The membranes were incubated with primary antibody 
at 4°C overnight, followed by incubation with HRP-conjugated 
secondary antibody. Protein bands were visualized by Amersham 
ECL Select™ detection reagent (GE Healthcare Life Sciences, 
Marlborough, MA, USA).
statistical analysis
Statistical analyses were performed using Graphpad Prism 5.03 
software (La Jolla, CA, USA). Unpaired two-tailed Student’s t-test 
was used to compare two groups with unmatched data. Welch’s 
correction was used when there was heterogeneity of variance. 
Paired two-tailed Student’s t-test was used to compare two groups 
with matched data. Two-way ANOVA was used to compare the 
mean values of more than two independent groups. P < 0.05 was 
considered statistically significant.
resUlTs
Mice Deficient in cr3 have a More 
activated nK Phenotype and Better  
nK-Dependent Tumor Killing
CD11b is the α-subunit of CR3, therefore CD11b−/− mice can-
not form functional CR3, and hence the interaction of CR3 
with ligand does not occur. It has been reported that NK cells 
from CD11b−/− mice displayed a more activated peripheral 
NK cell phenotype and had implications in liver disease (32). 
However, whether the CD11b−/− NK cell phenotype is relevant 
to malignancy is unknown. To address this, we first examined 
NK  cell maturation state in CD11b−/− and WT mice. There 
were similar percentages of NK1.1+CD3− (total NK  cells) or 
NK1.1+CD3-DX5+ (matured NK  cells) of splenic cells and 
bone marrow cells for CD11b−/− and WT mice, suggesting 
that CD11b−/− mice had a no alteration of NK cell maturation 
(Figure S1 in Supplementary Material). We also confirmed 
that peripheral NK  cells lacking CR3 (from CD11b−/− mice) 
exhibited increased expression of activating receptors/mark-
ers (NKp46 and CD69) and decreased expression of inhibitory 
receptor Ly49I/C, compared with CR3 sufficient NK  cells 
(from WT mice) (Figure S2 in Supplementary Material). 
Furthermore, we showed that NK cells lacking CR3 exhibited 
increased NK cell functional activity after exposure to tumor 
cells (measured by expression of CD107a and IFN-γ), com-
pared with CR3 sufficient NK cells (Figure 1A).
Next, we assessed whether lack of CR3 influences NK cyto-
toxicity in  vivo using an NK-dependent lymphoma rejection 
model (34). We initially confirmed that peritoneal NK  cells of 
CD11b−/− mice exhibited a more activated phenotype than that 
of WT mice (Figure S3 in Supplementary Material), and there 
was a large amount of deposition of activated C3 (C3b/iC3b) on 
tumor cells after 1 h of being injected into the peritoneal cavity 
(Figure S4 in Supplementary Material), indicating that sufficient 
ligands of CR3 can be generated rapidly. We then administered a 
mixture of NK-sensitive lymphoma cells (RMA-s) and NK-non-
sensitive lymphoma cells (RMA) in WT and CD11b−/− mice by 
intraperitoneal injection, the RMA cells being used as an internal 
control to normalize the remaining RMA-s cells. Four hours after 
the injection, we collected peritoneal lavage cells, performed flow 
cytometry, and calculated the remaining RMA-s cells. There were 
significantly fewer RMA-s tumor cells remained in CD11b−/−  
mice than that in WT mice, indicating that NK-dependent tumor 
cell killing is more efficient in CD11b−/− mice than that in WT 
mice (Figures 1B,C). These results demonstrate that lack of CR3 
leads to enhanced NK activity and effector function in tumor 
elimination, supporting a role for CR3 in NK  cell functional 
activity suppression.
FigUre 1 | Mice deficient in complement Receptor 3 have a more activated natural killer (NK) phenotype and better NK-dependent tumor killing. (a) Expression of 
CD107a and IFN-γ in purified NK cells of WT and CD11b−/− mice that had been cocultured with Yac-1 tumor cells. Left: representative flow cytometry dot plots showing 
percentage of CD107a+ or IFN-γ+ cells in gated NK1.1+CD3− cells. Right: quantification of percentage of CD107a+ or IFN-γ+ cells obtained from five mice per group, 
performed in five individual experiments. (B) Representative peritoneal lavage cell profiles of WT and CD11b−/− mice following intraperitoneal injection of tumor cells.  
(c) Quantification of remaining RMA-s cells from WT and CD11b−/− mice (n = 14, pooled from four individual experiments). Data in (a,c) were analyzed by unpaired 
two-tailed Student’s t-test, *P < 0.05, **P < 0.01, comparing CD11b−/− and WT mice. Each dot represents an individual mouse; small horizontal lines indicate the mean.
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cr3-Dependent suppression of nK cell 
Function has negative impact on Tumor 
surveillance
Given that NK cells play important roles in tumor surveillance 
(35), and NK cell functional activity is suppressed by CR3, we 
hypothesized that CR3-dependent suppression of NK cell func-
tion will have negative impact on tumor surveillance, and lack of 
CR3 will release the suppression and enhance NK cell-dependent 
tumor surveillance. To test this hypothesis, we employed a pul-
monary B16 melanoma metastases model and assessed tumor 
FigUre 2 | CD11b−/− mice have reduced metastatic tumor burden. (a) Schematic diagram of experimental design. WT or CD11b−/− mice received B16-luc 
melanoma cells by i.v. injection. Lung metastatic tumor burden was assessed at d 14 post tumor cell inoculation. (B) Bioluminescence imaging of B16-luc lung 
metastases. Left: representative bioluminescence images of WT and CD11−/− mice. Right: quantification of average radiance (p/s/cm2/sr) from the two groups of 
mice (n = 7/group, pooled from two separate experiments), and data were analyzed by unpaired t test with Welch’s correction, *P < 0.05. (c) Lung nodule analysis 
(d 14). Left: representative images of lungs from WT and CD11b−/− mice. Right: quantification of the number of tumor nodules on lung surface from the two groups 
of mice (n = 14/group, pooled from four separate experiments), and data were analyzed by unpaired two-tailed Student’s t-test.*P < 0.05. (B,c) Each dot 
represents an individual mouse; small horizontal lines indicate the mean.
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burden in the lung of CD11b−/− and WT mice. 14  days after 
intravenous inoculation of the melanoma cells, compared with 
WT mice, CD11b−/− mice had significantly reduced metastatic 
tumor burden measured by bioluminescence imaging analysis 
and less lung nodules measured by visually scoring surface 
tumor nodules (Figures  2A–C). These results clearly demon-
strate that CR3 has negative impact on tumor surveillance. We 
next assessed whether CR3-depedent suppression of NK  cell 
function contributes to the impairment of tumor surveillance. 
We employed an adaptive transfer of NK cell approach in the 
abovementioned melanoma metastasis model, except the recipi-
ent mice were E4bp4−/− mice (which had functional NK cell defi-
ciency) (32). We initially examined the engraftment of NK cells 
in E4bp4−/− mice. CR3-sufficient NK cells (from WT mice) and 
CR3-deficient NK  cells (from CD11b−/− mice) were similarly 
grafted in tumor bearing E4bp4−/− mice 24 h after intravenous 
injection of the NK cells (Figure S5 in Supplementary Material), 
which suggest that CR3-deficient NK cells have no apparent defect 
FigUre 3 | Mice that received CD11b−/− natural killer (NK) cells have less lung metastatic tumor burden than mice that received WT NK cells. (a) Schematic diagram 
of experimental design. NK cell-deficient mice (E4bp4−/−) that received B16-luc melanoma cells and NK cells from WT or CD11b−/− mice by i.v. injection at d 0, and 
received second dose of NK cells at d 7. Lung metastatic tumor burden was assessed at d 14 post tumor cell inoculation. (B) Bioluminescence imaging of B16-luc 
lung metastases. Left: representative bioluminescence images of mice received WT or CD11b−/− NK cells. Right: quantification of average radiance (p/s/cm2/sr) from 
the two groups of mice (n = 8/group). (c) Lung nodule analysis. Left: representative images of lungs from the mice received WT or CD11b−/− NK cells. Right: 
quantification of the number of tumor nodules on lung surface from the two groups of mice (n = 8/group). (B,c) The data were generated from two independent 
experiments and analyzed by unpaired two-tailed Student’s t-test.*P < 0.05. Each dot represents an individual mouse; small horizontal lines indicate the mean.
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in migration in this model. We then assessed the impact of the 
two groups of NK cells on tumor suppression. Following intrave-
nous inoculation of the melanoma cells, mice that received two 
doses (d0, d7) of CR3-deficient (CD11b−/−) NK cells by intra-
venous injection had significantly reduced metastatic tumor 
burden and less lung nodules, compared with the mice that 
received CR3-sufficient (WT) NK cells (Figures 3A–C), exhibit-
ing a similar level of reduction in tumor nodules and burden 
as observed in CD11b−/− mice (Figures 2A–C). These findings 
support that CR3-mediated suppression of NK cell function has 
a negative impact on tumor surveillance in this model.
ic3b-containing serum has negative 
effects on nK cell activity and Function
Next, we explored the mechanisms by which CR3 mediates 
the suppression of NK  cell function. iC3b is present in the 
circulation under normal conditions and known to increase 
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in certain pathological states including cancer (31), and solu-
ble iC3b can bind to CR3 on cell surface (29). Therefore, we 
investigated the effects of soluble iC3b on NK cell activity and 
function using freshly prepared human NK  cells and iC3b-
containing serum. We first measured iC3b levels in normal 
human serum and iC3b-containing serum (zymosan-treated 
normal serum) and examined whether iC3b binds to NK cells. 
iC3b was detected in normal serum and zymosan-treated 
serum (91.2 ± 4.8 and 361.2 ± 23.5 μg/ml, respectively), but 
not detected in control serum (zymosan-treated C3-depleted 
serum). Flow cytometry analysis showed that bound iC3b was 
detected on NK cell surface, following incubation of NK cells 
with iC3b-containing serum for 1  h, but was absent when 
NK cells were incubated with control serum, and the binding 
was effectively blocked by preincubation of iC3b-containing 
serum with N-acetyl-d-glucosamine (NADG) (a naturally 
occurring sugar that prevents iC3b binding to CR3), indicating 
that soluble iC3b can bind to NK cells, and the binding is CR3 
specific (Figure  4A). Next, we assessed the effects of iC3b-
containing serum on NK cell activity and function. Expression 
of the activating receptors/markers CD54, NKp46, and CD69 
was significantly reduced, whereas the inhibitory receptor 
CD158b was significantly increased on NK cells by incubation 
with iC3b-containing serum for 24 h, compared with control 
serum (Figures  4B,C). Accordingly, expression of NK  cell 
functional markers (i.e., CD107a, IFN-γ, granzyme B, and 
perforin) was significantly reduced on NK cells by incubation 
with iC3b-containing serum, following the stimulation with 
K562 tumor cells (Figures 4D–F). Furthermore, the effect of 
iC3b-containing serum on NK cell activity and function was 
blocked by NADG (Figure S6 in Supplementary Material). 
Together, these findings demonstrate that soluble iC3b can 
bind to CR3 on NK cells and negatively regulate NK cell activ-
ity and function.
Bound ic3b is a Potent negative 
regulator of human nK cell activity  
and Function
Apoptotic cells and cancer cells often have iC3b deposited on 
their cell surface. Next, we investigated the effects of bound iC3b 
on NK cell activity and function using freshly prepared human 
NK cells and iC3b-apoptotic cells. We first confirmed the deposi-
tion of iC3b on apoptotic cells following incubation with normal 
serum (20%, for 1 h) (Figure 5A). Then, we cocultured NK cells 
with iC3b-apopototic cells or control cells (apoptotic cells prein-
cubated with C3-depleted serum) for 24 h and assessed NK cell 
activity and function by flow cytometry. NK cells that had been 
cocultured with iC3b-apoptotic cells exhibited significantly lower 
levels of CD69 and functional markers (CD107a, IFN-γ) than 
that cocultured with control cells (Figures 5B,C). Furthermore, 
NK  cells pre-cocultured with iC3b-apopototic cells induced 
less efficient killing of target cells, including the direct killing of 
NK-sensitive K562 tumor cells and ADCC of rituximab-coated 
Raji cells (Figures 5D,E). Collectively, these findings demonstrate 
that cell-bound iC3b can effectively suppress NK cell activity and 
cytotoxic function.
identification of intracellular signaling 
Pathways responsible for the action of 
ic3b on nK cell Functional regulation
Having demonstrated that iC3b has negative effects on NK cell 
activity and effector function, we next sought to identify the sig-
nal transduction pathways through which iC3b may negatively 
affect NK cells. Binding of ligands to integrin (outside-in signal-
ing) triggers a variety of intracellular signaling. Activation of the 
Src homology 2 domain-containing inositol-5-phosphatase-1 
(SHIP-1) and downregulation of JNK and MAPK activation 
have been suggested as important signal transduction pathways 
involving negative regulation of cellular responses in different 
types of cells (e.g., macrophage, B cell, and NK cell) (36, 37). We 
hypothesized that CR3 may suppress NK cell function through 
the abovementioned intracellular pathways. We stimulated 
human NK cells with cell-bound iC3b and analyzed the changes 
of phosphorylation of SHIP-1, ERK, JNK, AKT, and P38 in 
NK cells. Phosphorylation of SHIP-1 and JNK were upregulated, 
in contrast, the ERK was downregulated by iC3b stimulation, as 
measured by both flow cytometry (Figure S7 in Supplementary 
Material) and Western blot (Figures  6A–C). No significant 
changes were observed in AKT and P38 phosphorylation fol-
lowing iC3b stimulation (Figure S8 in Supplementary Material). 
In addition, blockade of iC3b binding to CR3 by preincubation 
of iC3b with NADG significantly inhibited the effects of iC3b 
on SHIP-1 phosphorylation (Figure  6D). To assess whether 
these intracellular signaling pathways responsible for the 
action of iC3b on NK cell functional regulation, we pretreated 
human NK  cells with specific inhibitor of SHIP-1 (3AC) (33), 
ERK (U0126) and JNK (SP600125) and then assessed NK  cell 
functional activity by flow cytometry, percentage of CD107a+ 
NK cells or IFN-γ+ NK cells significantly increased by SHIP-1 or 
JNK inhibition, but decreased by ERK inhibition (Figures 6E,F). 
Collectively, Western blot and flow cytometry analyses reveal 
that iC3b stimulation causes the activation of SHIP-1 and JNK 
and suppression of ERK in human NK cells; pathway inhibition 
experiments indicate that SHIP-1, JNK, and ERK are important 
NK cell signaling pathways, supporting that iC3b mediates nega-
tive regulation on NK cell functions through activation of SHIP-1 
and JNK and inhibition of ERK signaling.
DiscUssiOn
Several lines of emerging evidence have challenged the tradi-
tional concept about the role of complement in tumor surveil-
lance. Tumor cells were often thought to develop resistance to 
complement mediated killing by increasing the expression of 
complement regulatory proteins, which promotes the conversion 
of C3b (active) to iC3b or C3d (inactive), thus preventing C5b-9 
formation (38). In this context, previous studies have shown that 
complement C3- or C5-deficient mice had reduced tumor growth; 
complement cleavage products (e.g., C5a) through engagement 
with their receptors on immune cells negatively regulate anti-
tumor immunity and subsequently promote tumor growth or 
metastasis (39, 40). Furthermore, rituximab-mediated lymphoma 
killing did not benefit from the activation of complement (41, 42). 
FigUre 4 | Continued
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These studies clearly suggest that complement activation can 
contribute to tumor growth and metastasis through different 
mechanisms. In the present study, we show that CR3 impairs 
tumor surveillance by suppression of NK  cell function, which 
provides novel insight into dysregulation of tumor surveillance 
by complement.
Although iC3b/CR3 axis has been implicated in pancreatic 
carcinoma (29, 31), it is unknown whether CR3 can more 
FigUre 4 | iC3b-containing serum has negative effects on natural killer (NK) cell activity and function. Purified human NK cells from healthy donors were incubated 
with or without 10% of the following sera [including zymosan-treated normal serum (iC3b-S), zymosan-treated C3-depleted serum (Control-S) or iC3b-S plus 50 mM 
N-acetyl-d-glucosamine (NADG)] for different time periods. (a) Flow cytometric analysis of deposition of iC3b on NK cells (1 h after the incubation) using mouse 
anti-human iC3b (neo) antibody. A representative of three independent experiments with three cell preparations is shown. (B,c) Flow cytometric analysis of surface 
expression of activating [CD54, NKp46, CD69, in (B)] and inhibitory (CD158b), in (c) receptors on NK cells (24 h after the incubation). (D–F) Flow cytometric 
analysis of expression of NK cell functional markers (CD107a, Granzyme B, and perforin) and production of IFN-γ in NK cells that had been incubated with serum for 
24 h and further stimulated with K562 tumor cells. (B–F) The results were derived from six to eight experiments using different blood donors and analyzed by paired 
two-tailed Student’s t-test. *P < 0.05, **P < 0.01.
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FigUre 5 | Bound iC3b is a potent negative regulator of natural killer (NK) cell activity and function. (a) Apoptotic Jurkat cells were incubated with either normal 
serum or C3-depleted serum for 1 h, and the deposition of iC3b on the surface was analyzed by flow cytometry using mouse anti-human iC3b (Neo) antibody.  
(B–e) Purified human NK cells from healthy donors were incubated with normal serum pretreated-apoptotic cells (iC3b-AC) or C3-depleted serum pretreated 
apoptotic cells (Control-AC) for 24 h and NK cell activity and function were assessed. (B) Flow cytometric analysis of surface expression of CD69 on gated 
CD56+CD3− cells. (c) Expression of CD107a and production of IFN-γ in gated NK cells that had been further stimulated with K562 cells. (D) Direct killing of 
NK-sensitive K562 tumor cells by NK cells that had been pretreated with iC3b-AC or Control-AC. (e) Antibody-dependent cell-mediated cytotoxicity of rituximab-
coated Raji cells assay was performed by using NK cells that had been pretreated with iC3b-AC or Control-AC. (B,c) Data were derived from 6 to 12 experiments 
using different blood donors and analyzed by paired two-tailed Student’s t-test. **P < 0.01, ***P < 0.001. (D,e) Data were generated from three independent 
experiments, with triplicate samples/group in each experiment and analyzed by two-way ANOVA.
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specifically through its effects on NK  cells influence tumor 
surveillance. To investigate this, we employed several well-
established animal models to assess NK cell anti-tumor activity 
in vivo (34, 43) and a series of in vitro analyses to assess NK cell 
activity and tumor cell killing function. Using the pulmonary 
B16 melanoma metastases model, we found that CR3-deficient 
mice conferred protection against lung metastases, suggesting 
that CR3 plays a critical role in suppression of anti-tumor 
immunity in this model. Combining an adaptive transfer of 
NK  cell approach to the melanoma metastases model, we 
found that CR3-deficient NK cells mediated better anti-tumor 
responses than CR3-sufficient NK  cells, defining the role of 
FigUre 6 | Continued
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FigUre 7 | Schematic diagram illustrates that both soluble and cell-bound 
iC3b could mediate natural killer (NK) cell suppression. iC3b, either in soluble 
or cell-bound form, interacts with complement receptor 3 (CR3) expressed 
on NK cells, which induces suppression of NK cell function through 
receptor-mediated intracellular signaling pathways.
FigUre 6 | Continued  
Identification of intracellular signaling pathways responsible for the action of iC3b on natural killer (NK) cell functional regulation. (a–c) Western blot for detection of 
phosphorylation of Src homology 2 domain-containing inositol-5-phosphatase-1 (SHIP1), ERK1/2, and JNK (MAPK) was performed in purified human NK cells that 
had been stimulated with bound iC3b (iC3b-AC) for indicated time periods. In each blot the top of bands corresponds to incubating membrane with appropriate 
phospho-antibody, and the bottom row of bands corresponds to incubating membrane with appropriate total antibody. Relative amounts of p-SHIP1, p-ERK1/2, 
and p-JNK are shown in the lower panel of the each figure. A representative of 3–4 independent experiments is shown. (D) Western blot for detection of SHIP1 was 
performed in purified human NK cells that had been stimulated with N-acetyl-d-glucosamine (NADG) pretreated iC3b-AC for indicated time periods. (e,F) Effect of 
inhibition of SHIP1, ERK1/2, and JNK pathways on CD107a expression and IFN-γ production in NK cells. Purified NK cells were further cultured for 16 h in the 
presence or absence of the appropriated inhibitor (i.e., 3-alpha-aminocholestane for SHIPI, U0126 for ERK, SP600125 for JNK) and the vehicle control then were 
used for functional assays. Results are presented as percentage of CD107a+ or IFN-γ+ cells in gated CD56+D3− cells. Data were expressed as mean ± SEM of four 
independent experiments and analyzed by paired two-tailed Student’s t-test. **P < 0.01, ***P < 0.001. (g) Proposed intracellular signaling pathways responsible for 
the action of iC3b on NK cell functional suppression. iC3b stimulation mediates activation of SHIP and JNK and inhibition of ERK, which lead to suppression of 
NK cell function.
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CR3 in suppression of NK-dependent anti-tumor immunity. 
Using the NK-dependent peritoneal tumor elimination model, 
we found that CR3-deficient mice rejected lymphoma cells 
better than WT mice, further supporting the role of CR3 in 
NK  cell functional suppression. Therefore, results obtained 
from our in vivo experiments suggest that CR3 has strong sup-
pressive effects on NK cell function that impairs NK-mediated 
anti-tumor responses.
Our in  vitro analyses found that both soluble and bound 
iC3b can suppress NK  cell function through interaction with 
CR3. These observations for several reasons could have in vivo 
relevance. First, soluble iC3b is present in the circulation under 
normal conditions and increases in certain pathological states 
including cancer, as a result of increased complement activation 
(31). In cancer, the deposited iC3b could be shed from tumor 
cells to further increase iC3b levels in the circulation (29). Thus, 
although low levels of iC3b present in the circulation under 
normal conditions may only have minimal effects on NK cells, in 
the presence of tumor cells, elevated soluble iC3b may enhance 
its interaction with CR3 on NK  cells which mediates NK  cell 
suppression. In addition, tumor cells often have elevated iC3b on 
the cell surface as a result of upregulating complement regulator 
expression. Deposited iC3b on tumor and apoptotic cells may 
interact with CR3 on NK cells to mediate NK cell suppression. 
Therefore, soluble and bound iC3b, either in the circulation or 
within the tumor microenvironment, could mediate NK cell sup-
pression, as illustrated in Figure 7.
In addition to the relevance to tumor surveillance, our results 
in ADCC analysis also suggest that iC3b/CR3-mediated NK cell 
suppression may have the implications in antibody-based cancer 
therapies. Traditionally, it is thought that complement plays 
important roles in antibody-mediated therapies through mediat-
ing complement-dependent cytotoxicity (CDC) and antibody-
dependent NK  cell cytotoxicity. However, for the CDC, there 
is no clear evidence that serum (more specifically, complement 
activity) is required for the effects of therapeutic antibodies, 
possibly reflecting the tumor cells developed strategy to prevent 
C5b-9 formation (38, 44). For ADCC, in contrast to enhancement 
of NK cell cytotoxicity suggested by early studies (44, 45), recent 
studies have shown that C3b fixation on target cells inhibited 
NK  cell activation and impaired ADCC (41, 42). Therefore, 
these evidence, together with our observation that addition of 
iC3b impaired rituximab-dependent cytotoxicity by NK cells in 
ADCC assays, suggest that, in the context of failure to mediate 
tumor cell lysis, complement activation may have negative impact 
on antibody-based cancer therapies through iC3b/CR3-mediated 
NK cell suppression.
Another important aspect of our in  vitro observations is 
identifying the signal transduction pathways through which 
iC3b negatively affects NK activation and function. SHIP (also 
known as SHIP1) is well characterized as a negative regulator 
of immune cells (36). It has been shown that SHIP-1 can be 
phosphorylated following activation of various membrane 
receptors (e.g., BCR, FcR, and TCR) (46, 47). SHIP can also 
regulate many other intracellular signaling such as AKT, JNK, 
and MARK through its catalytic activity or non-catalytic activ-
ity (37). SHIP has been suggested playing important roles in 
CD16-mediated downregulation of NK  cell cytotoxicity and 
IFN-γ production (48, 49). A recent study, in mouse models 
of lymphoma and colon cancer, has shown that transient and 
pulsatile inhibition of SHIP1 increased both NK and T  cell 
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responsiveness and reduced the growth of hematological and 
solid tumors in mice. These findings further support a role 
for SHIP1 signaling in suppression of NK  cell function and 
immunosuppression in cancer (50). However, it has been 
unknown whether SHIP involves CR3-mediated negative 
regulation of NK cell function. Our results clearly showed that 
iC3b stimulation caused an increase in the phosphorylation of 
SHIP, in agreement with this observation, it has been reported 
that SHIP was involved in integrin signaling in platelets (51). 
Therefore, given the roles of SHIP 1 in suppression of NK cell 
function and tumor immunity, our results strongly support 
the notion that SHIP signaling driven by iC3b/CR3 interac-
tions in NK cells has negative impact on NK cell function and 
NK-dependent tumor surveillance. Our results also showed 
that increased SHIP phosphorylation was accompanied by 
a decrease in ERK1/2 phosphorylation, this is in agreement 
with the role of SHIP in inhibition of downstream signaling 
of MAPK as previously reported (52), and thus suggesting a 
SHIP-dependent ERK regulation. Although inhibition of JNK 
signaling by SHIP has been reported in other cells (e.g., B cells) 
(37), this was not observed in our study. On the other hand, 
we found that iC3b stimulation increased the phosphorylation 
of JNK in NK cells, suggesting that iC3b regulation of JNK is 
SHIP independent. In agreement with our observation, it has 
been suggested that CD11b (CR3) could involve the inhibition 
of NK  cell function through activation of JNK pathway (53). 
Thus, our signaling experiments identified signaling transduc-
tion pathways responsible for iC3b/CR3-mediated NK cell sup-
pression, namely activation of SHIP and JNK and suppression 
of ERK (Figure 6G).
In summary, the present study showed that CR3 impairs tumor 
surveillance by suppression of NK  cell function and defined 
intracellular signaling pathways by which iC3b/CR3 interactions 
mediate NK cell suppression. Our findings provide new insight 
into the paradoxical effect of innate immune responses on tumor 
surveillance, such as complement activation and suggest that 
iC3b/CR3 axis is a potential therapeutic target for preserving 
NK cell function and improving NK cell-based therapy.
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